[go: up one dir, main page]

BRPI0408153A - formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo - Google Patents

formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo

Info

Publication number
BRPI0408153A
BRPI0408153A BRPI0408153-6A BRPI0408153A BRPI0408153A BR PI0408153 A BRPI0408153 A BR PI0408153A BR PI0408153 A BRPI0408153 A BR PI0408153A BR PI0408153 A BRPI0408153 A BR PI0408153A
Authority
BR
Brazil
Prior art keywords
treating individual
formulations
methods
kit
formulation
Prior art date
Application number
BRPI0408153-6A
Other languages
English (en)
Inventor
Dario Norberto R Carrara
Arnaud Grenier
Celine Besse
Stephen M Simes
Leah M Lehman
Original Assignee
Antares Pharma Ipl Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antares Pharma Ipl Ag filed Critical Antares Pharma Ipl Ag
Publication of BRPI0408153A publication Critical patent/BRPI0408153A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES PARA ADMINISTRAçãO TRANSDéRMICA OU TRANSMUCOSA DE AGENTE ATIVO, MéTODOS DE TRATAMENTO DE DISTúRBIOS HORMONAIS EM INDIVìDUO, USOS DE FORMULAçãO E DE MELHORADOR DE PERMEAçãO E KIT PARA TRATAMENTO DE INDIVìDUO". A invenção refere-se a usos e formulações para proporcionar liberação transdérmica e transmucosa de agentes ativos para indivíduos necessitando deles. As formulações e métodos tratam sintomas de distúrbios hormonais que incluem hipogonadismo, distúrbio do desejo sexual feminino, distúrbio de menopausa feminina e insuficiência adrenal.
BRPI0408153-6A 2003-03-11 2004-03-11 formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo BRPI0408153A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45360403P 2003-03-11 2003-03-11
US51061303P 2003-10-10 2003-10-10
US10/798,111 US20040198706A1 (en) 2003-03-11 2004-03-10 Methods and formulations for transdermal or transmucosal application of active agents
PCT/US2004/007291 WO2004080413A2 (en) 2003-03-11 2004-03-11 Uses and formulations for transdermal or transmucosal application of active agents

Publications (1)

Publication Number Publication Date
BRPI0408153A true BRPI0408153A (pt) 2006-04-04

Family

ID=33102163

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408153-6A BRPI0408153A (pt) 2003-03-11 2004-03-11 formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo

Country Status (13)

Country Link
US (1) US20040198706A1 (pt)
EP (1) EP1648406A4 (pt)
JP (2) JP4864695B2 (pt)
KR (1) KR20050106508A (pt)
CN (1) CN105853396A (pt)
AU (1) AU2004220498B2 (pt)
BR (1) BRPI0408153A (pt)
CA (1) CA2515426C (pt)
HK (1) HK1225311A1 (pt)
IL (1) IL170454A (pt)
MX (1) MXPA05008648A (pt)
NZ (1) NZ541854A (pt)
WO (1) WO2004080413A2 (pt)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
EP1307232B1 (en) * 2000-08-03 2007-03-07 Antares Pharma IPL AG Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
EP1556009B2 (en) 2002-10-25 2021-07-21 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US7704516B2 (en) * 2003-04-01 2010-04-27 Laboratories Besins International Sa Percutaneous composition comprising 4-hydroxy tamoxifen
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
BRPI0414551B8 (pt) * 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20090017047A1 (en) * 2004-06-11 2009-01-15 Egon Tech Preparation for the Prevention and Treatment of Stress Conditions as Well as Functional and Organic Disorders of the Nervous System and Metabolic Disorders
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
RS20070166A (sr) 2004-10-20 2008-09-29 Endorecherche Inc., Prekursori seksualnih steroida sami ili u kombinaciji sa selektivnim modulatorom estrogenskog receptora i/ili sa inhibitorom cgmp fosfodiesteraze tipa 5 za prevenciju ili tretman isušenosti vaginalne sluzokože i seksualne disfunkcije kod žena u postmenopauzi
AP2007003982A0 (en) * 2004-11-01 2007-06-30 Endorech Inc Use of androgens to reduce the likelihood of acquring or to treat skin aging
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
BRPI0611134A2 (pt) * 2005-06-03 2010-08-17 Acrux Dds Pty Ltd método e composição para liberação transdérmica de fármaco
AU2006254742C1 (en) * 2005-06-03 2011-11-03 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
CA2610708C (en) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
EP1983998A2 (en) * 2006-01-20 2008-10-29 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
ITRM20060154A1 (it) * 2006-03-20 2007-09-21 Alexandra Fede Composizione e metodo per la applicazione di di fenomeni umani sintetici con bio capsula tecnologica a lento rilascio di sostanze tramite gocce in indumenti biancheria gioielleria e simili
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US9693953B2 (en) * 2006-06-02 2017-07-04 Janet A. Chollet Method of treating atrophic vaginitis
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20100093754A1 (en) * 2007-03-28 2010-04-15 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2010125468A1 (en) 2009-05-01 2010-11-04 Ferring International Center Sa Composition for the treatment of prostate cancer
AU2010202421B2 (en) * 2009-06-15 2014-05-08 Gojo Industries, Inc. Method and compositions for use with gel dispensers
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
WO2011073995A2 (en) 2009-12-14 2011-06-23 Lincoln Pharmaceuticals Limited Liquid vaginal spray of progesterone
PT2632934T (pt) 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
AU2011329782A1 (en) 2010-11-18 2013-06-20 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AU2012257491A1 (en) * 2011-05-13 2013-12-12 Acerus Pharmaceuticals Srl Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
JP6152092B2 (ja) * 2011-05-15 2017-06-28 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
JP6285354B2 (ja) * 2011-06-27 2018-02-28 フェリング ベスローテン フェンノートシャップ ヒトの皮膚に粘稠な液体を適用するためのアプリケーターシステム
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
PL2903608T3 (pl) 2012-10-03 2019-12-31 Proponent Biotech Gmbh Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
PH12016500425B1 (en) 2013-09-05 2022-07-29 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
CA2967375C (en) 2014-11-14 2023-08-15 Follea International System and method for preventing alopecia
JP7274259B2 (ja) 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
JP2018512450A (ja) 2015-03-19 2018-05-17 ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ 女性の性的障害を治療するための化合物及び剤型
WO2016201286A1 (en) 2015-06-11 2016-12-15 Applied Biology, Inc. Treatment of sexual dysfunction
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
AU2017259104B2 (en) * 2016-05-02 2019-01-03 TA Pharma Pty Ltd Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
US11813354B1 (en) * 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2021224432A1 (en) 2020-05-06 2021-11-11 Ab2 Bio Sa Il-18 binding protein (il-18bp) in respiratory diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
US20250179131A1 (en) 2022-03-04 2025-06-05 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
GB202402524D0 (en) * 2024-02-22 2024-04-10 Futura Medical Developments Ltd Topical composition

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US4338993A (en) * 1980-02-22 1982-07-13 R. W. Fernstrum & Co. Underwater outboard marine heat exchanger
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US5731303A (en) * 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5925372A (en) * 1987-12-16 1999-07-20 Novartis Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5225189A (en) * 1988-02-18 1993-07-06 The Upjohn Company Minoxidil gel
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
EP0409383B1 (en) * 1989-07-21 1994-04-06 Izhak Blank Estradiol compositions and methods for topical applications
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
US5230896A (en) * 1989-10-12 1993-07-27 Warner-Lambert Company Transdermal nicotine delivery system
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602017A (en) * 1990-04-10 1997-02-11 Kyowa Hakko Kogyo Co., Ltd. Cholesterol oxidase
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US5178879A (en) * 1992-04-17 1993-01-12 Michael Adekunle Capsaicin gel
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
JP2937667B2 (ja) * 1992-11-19 1999-08-23 高砂香料工業株式会社 尋常性ざ瘡用皮膚外用剤
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE69422925T2 (de) * 1993-07-09 2000-08-17 Cygnus, Inc. Verfahren und vorrichtung für die transdermale oder transbuccale therapeutische verabreichung von nikotinsubstituten
US5549888A (en) * 1994-01-31 1996-08-27 Procter & Gamble Aqueous topical anti-acne compositions of low pH
CN1106259A (zh) * 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
FR2722102B1 (fr) * 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
US6309843B1 (en) * 1994-10-25 2001-10-30 The Curators Of The University Of Missouri Glycoprotein for use in determining endometrial receptivity
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
EP0785212A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New 19-nor-pregnene derivatives
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
GB9610862D0 (en) * 1996-05-23 1996-07-31 Evans Brian K Pharmaceutical products
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US20010023261A1 (en) * 1997-01-27 2001-09-20 Lg Chemical Limited. Novel composition for the transdermal administration of drugs
US6426078B1 (en) * 1997-03-17 2002-07-30 Roche Vitamins Inc. Oil in water microemulsion
PT986403E (pt) * 1997-06-13 2004-04-30 Cydex Inc Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
NZ504423A (en) * 1997-11-10 2003-04-29 Cellegy Pharma Inc Composition having enhanced penetration capabilities and irritation reducing systems
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
ES2310042T3 (es) * 1998-07-07 2008-12-16 Transdermal Technologies Inc. Composiciones para la administracion transdermica rapida y no irritante de agentes farmaceuticamente activos y procedimientos para formular dichas composiciones y administracion de las mismas.
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6451300B1 (en) * 1999-05-03 2002-09-17 The Procter & Gamble Company Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
FR2798065B1 (fr) * 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
CN101305994A (zh) * 2000-04-26 2008-11-19 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
EP1307232B1 (en) * 2000-08-03 2007-03-07 Antares Pharma IPL AG Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
CA2359813C (en) * 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
WO2002055020A2 (en) * 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
JP4707297B2 (ja) * 2001-03-23 2011-06-22 ロート製薬株式会社 外皮用組成物
US6951846B2 (en) * 2002-03-07 2005-10-04 The United States Of America As Represented By The Secretary Of The Army Artemisinins with improved stability and bioavailability for therapeutic drug development and application
DE10253216A1 (de) * 2002-11-15 2004-05-27 Cognis Deutschland Gmbh & Co. Kg Verwendung von niedermolekularen Proteinhydrolysaten in Wasch- und Reinigungsmitteln
US6995265B2 (en) * 2003-08-26 2006-02-07 North Carolina State University Synthesis of nicotine derivatives from nicotine
BRPI0414551B8 (pt) * 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20070048360A1 (en) * 2005-08-23 2007-03-01 R Carrara Dario N Pharmaceutical compositions with melting point depressant agents and method of making same

Also Published As

Publication number Publication date
CA2515426A1 (en) 2004-09-23
JP4864695B2 (ja) 2012-02-01
EP1648406A2 (en) 2006-04-26
US20040198706A1 (en) 2004-10-07
JP2007524589A (ja) 2007-08-30
EP1648406A4 (en) 2012-03-21
JP5441966B2 (ja) 2014-03-12
AU2004220498A1 (en) 2004-09-23
KR20050106508A (ko) 2005-11-09
IL170454A (en) 2014-02-27
NZ541854A (en) 2008-05-30
CN105853396A (zh) 2016-08-17
WO2004080413A2 (en) 2004-09-23
HK1225311A1 (zh) 2017-09-08
CA2515426C (en) 2012-01-24
AU2004220498B2 (en) 2009-04-23
JP2011236250A (ja) 2011-11-24
WO2004080413A3 (en) 2006-07-20
MXPA05008648A (es) 2006-02-10

Similar Documents

Publication Publication Date Title
BRPI0408153A (pt) formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo
MA26843A1 (fr) NOUVELLES COMPOSITIONS ESTRO-PROGESTATIVES TOPIQUES à EFFET SYSTÉMIQUE
MXPA03001858A (es) Metodo para el tratamiento de la disfuncion erectil e incremento en el libido del hombre.
EP1429729A4 (en) COMBINED METHOD OF FORMING WITH A CHOLESTERIC STRENGTH, A RENIN-ANGIOTENSIN-INHIBITOR AND ACETYL-SALICYLIC ACID
AR035131A1 (es) Composiciones topicas y metodos para el tratamiento del dolor
IS8726A (is) Meðferðarfræðilegar samsetningar þrýstingslækkandi efna og efna sem hamla gegn æðamyndun
MXPA05002814A (es) Formulacion para agentes lipofilicos.
NZ536633A (en) Percutaneous delivery of testosterone via a hydroalcoholic gel as a method of increasing testosterone and related steroid concentrations in women
DE60138468D1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
BR0200246A (pt) Tratamento de combinação para a depressão
ATE407690T1 (de) Topische pharmazeutische zusammensetzungen enthaltend aktive natürliche bestandteile zur verhütung und behandlung von mucosalen entzündungprozessen
NO20043001D0 (no) Farmasoytisk formulering omfattende cyklosporin og anvendelse derav
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
TW200511996A (en) The use of steroids to treat persons suffering from ocular disorders
AR036970A1 (es) Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion
ATE395061T1 (de) Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
ES2169942T3 (es) Uso de preparaciones topicas de trinitrato de glicerilo y lanolina para el tratamiento de la disfuncion erectil.
BRPI0517950A (pt) uso de andrógenos para reduzir a probabilidade de adquirir ou para o tratamento do envelhecimento da pele
US8268364B1 (en) Water based pain relieving composition
BR0005319A (pt) Tratamento combinado para depressão e ansiedade

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/56, 47/10, 9/00, 9/06; A61P 9/06, 5/00, 5/30, 5/34

Ipc: A61K 31/56 (2011.01), A61K 47/10 (2011.01), A61K 9

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O COMBINADO COM ARTS. 11 E 13 E ARTS. 10 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]